A.R.T. Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

A.R.T. Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-36,193	Closed	-$797K	–	1194
2019 Q4	$797K	Buy	36,193 +1,500	+4%	+$30.2K	0.04%	653
2019 Q3	$498K	Buy	+34,693	New	+$496K	0.02%	869
2018 Q3	–	Sell	-30,646	Closed	-$375K	–	1828
2018 Q2	$375K	Buy	+30,646	New	+$385K	0.02%	1021
2017 Q4	–	Sell	-17,650	Closed	-$101K	–	1777
2017 Q3	$101K	Buy	+17,650	New	+$64.2K	0.01%	1209
2017 Q1	–	Sell	-11,256	Closed	-$32K	–	1810
2016 Q4	$32K	Buy	+11,256	New	+$40K	﹤0.01%	1230
2016 Q3	–	Sell	-56,763	Closed	-$170K	–	1315
2016 Q2	$170K	Buy	+56,763	New	+$233K	0.01%	1139
2015 Q3	–	Sell	-58,398	Closed	-$814K	–	1695
2015 Q2	$814K	Buy	58,398 +30,650	+110%	+$562K	0.03%	807
2015 Q1	$666K	Buy	+27,748	New	+$624K	0.02%	808

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

A.R.T. Advisors's DRNA Position: Q1 2020 in Review

A.R.T. Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020, closing a stake of 36,193 shares — an estimated $797K sold.

A.R.T. Advisors first reported a position in DRNA in Q1 2015 and held it in 8 quarters. The position peaked at $814K in Q2 2015. 144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

A.R.T. Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 36,193 Dicerna Pharmaceuticals, Inc. shares in Q1 2020, an estimated $797K.
A.R.T. Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 8 quarters.
A.R.T. Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $814K in Q2 2015.
144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.